ArsenalBio Stock

HealthTech

Looking to sell ArsenalBio stock or options?

Founded: 2019Funding to Date: $340M

ArsenalBio operates as a programmable cell therapy company with a purpose to discover, develop, and market curative immune cell therapies. The company features a comprehensive research and development engine that creates multifunctional T-cell medicines, made possible by the accurate and specific insertion of large synthetic deoxyribonucleic acid sequences. Therefore, ArsenalBio provides clinicians with advanced autologous T-cell therapies to conquer cancer.

Investors include:

Further Key Investors:

Kenneth Drazan, Green Sands Equity, UCSF Foundation Investment Company, Byers Capital, Triatomic Capital, University of California, Parker Institute for Cancer Immunotherapy, Waycross Ventures, Bristol-Myers Squibb, Osage University Partners, Emerson Collective, Westlake Village BioPartners, Hitachi Ventures, Sixth Street Partners, SoftBank Investment Advisers, Euclidean Capital.

Looking to sell ArsenalBio Stock or Options?

We have an even better solution: The Collective Exchange Fund

Get in touch and see if we can help you